This event will explore novel and emerging non-clinical ADME approaches, structure based prediction of ADME properties, PK/PD modelling to validate drug targets, toxicity and much more.ADMET 2016 will provide a series of practical case studies, interactive roundtables and panel discussions facilitated by leading industry experts that will provide executives with useful tools and best practices to:• Discover application of PBPK to drug development in rare diseases • Review the role of drug transporters in drug delivery to CNS diseases • Learn about better models for understanding, predicting and avoiding drug induced liver injury • Discuss in silico approaches to evidence-based mechanistic modelling • Analyse early dose predictions – a valuable tool in risk assessment and optimisation of small molecules2016 Speaker Line up:CHAIRMAN:• Thierry Lave, Head DMPK Discovery and Development Project Leaders (CNS/CVM), RocheKEYNOTE SPEAKERS:• Friedemann Schmidt, R&D DSAR Preclinical Safety, Sanofi-Aventis• Kunal Taskar, Senior Investigator, DMPK, GSK• Karelle Menochet, Principal Scientist DMPK, UCB Pharma• Laurent Salphati, Senior Scientist, Genentech• Carl Petersson, DMPK NCE Senior Designer, Merck Serono• Lena Gustavsson, Head of Sections Drug-Drug Interactions, LundbeckHow to register:EARLY BIRD offers availableVisit the event website